Compare Amplify Cybersecurity ETF (HACK) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Cybersecurity ETF vs Heron Therapeutics Inc — how do they compare? Amplify Cybersecurity ETF trades at $123.68 (market cap $3.55B), while Heron Therapeutics Inc trades at $0.37 (market cap $74.04M). The key difference: Amplify Cybersecurity ETF is far larger — about 47.9× Heron Therapeutics Inc's market cap, and Amplify Cybersecurity ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 30 Days and Heron Therapeutics Inc for 35 Days on average.
| HACK | HRTX | |
|---|---|---|
Market Cap | $3.55B | $74.04M |
Volume | 233,961 | 3,668,095 |
Sector | Sector/Thematic | Health |
52-Week High | $127.66 | $1.49 |
52-Week Low | $70.69 | $0.27 |
Typical Hold Time | 30 Days | 35 Days |
Enterprise Value | — | $180.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HACK trades at $125.81, down 1.45% today but near its 52-week high, with a strong technical outlook showing bullish moving averages and key support at $124. Recent news highlights the ETF's momentum, driven by AI safety concerns and cybersecurity demand, with the fund up 84.96% from its 52-week low. Financial ratios are not disclosed for this ETF, but sector growth remains a tailwind.
The outlook for HACK is positive, supported by rising cybersecurity spending and AI-driven threats, though risks include increased short interest and sector volatility. Analyst sentiment is bullish, with the ETF positioned to benefit from ongoing digital security trends, but investors should monitor competitive and macroeconomic pressures.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
